Higher doses of topical corticosteroids linked to increased risks of osteoporosis and bone fractures

New research indicates that higher doses of topical corticosteroids, which are commonly used to treat inflammatory skin conditions, are linked with elevated risks of osteoporosis and bone fractures associated with osteoporosis.

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

Share this article Johnson & Johnson’s OPSYNVI is a single-tablet formulation comprising macitentan and tadalafil. Credit: Manuel Esteban / Shutterstock.com. The US Food and Drug

March 25, 2024

Astellas to close facility in California; Takeda can make more of its ADHD drug

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Astellas Gene Therapies is shuttering its

September 6, 2024

FDA leaders kick off rare disease hub to increase cross-center collaboration

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.